Rhelion Life Sciences Corp. TRUFF
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -79.19% | -30.62% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -79.19% | -30.62% | |||
| Cost of Revenue | -96.16% | -53.93% | |||
| Gross Profit | -63.77% | 28.48% | |||
| SG&A Expenses | -3.13% | -0.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.98% | -19.94% | |||
| Operating Income | -29.31% | 8.64% | |||
| Income Before Tax | 57.20% | -138.99% | |||
| Income Tax Expenses | -- | -722.44% | |||
| Earnings from Continuing Operations | 54.07% | -127.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -96.78% | 1,977.16% | |||
| Net Income | 27.70% | -83.79% | |||
| EBIT | -29.31% | 8.64% | |||
| EBITDA | 31.85% | -75.94% | |||
| EPS Basic | 44.19% | -79.17% | |||
| Normalized Basic EPS | -- | 100.00% | |||
| EPS Diluted | 80.49% | -412.50% | |||
| Normalized Diluted EPS | -- | 100.00% | |||
| Average Basic Shares Outstanding | 29.86% | 1.69% | |||
| Average Diluted Shares Outstanding | 29.86% | 1.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||